CombiGene´s lead project CG01 has received funding from the European Union´s Horizon 2020 research and innovation programme

Board of Directors

Shareholdings are correct as at December 12 2018, and are updated every year.

Arne Ferstad

Chairman of the Board, elected 2014. (b. 1950)
Education and experience: Arne Ferstad, bachelor’s degree in Market Economy, CEDEP/INSEAD, has a broad range of experience in the biotech and pharmaceutical industries, including business development and international marketing. He is the CEO and Director of Ankor Consultants Ltd. He was previously in charge of Baxter Healthcare’s business in the Nordic and Benelux countries, President of EMEA Baxter Renal Division, head of Baxter’s bioscience business in Asia and held several senior positions in Baxter R&D. Arne was also General Manager and Vice President at Pharmacia Corporation.
Current assignments: CEO and Chairman of the Board of Ankor Consultants Ltd. Board member of Peptonic Medical AB (publ) and Clinical Laserthermia Systems AB (publ).
Previous assignments: Board member of Cline Scientific AB and Neurovive Pharmaceutical AB (publ). Chairman of the Board of AroCell AB, Medfield Diagnostics AB (publ) and Aggancio Research AB.
Owner and active in the following companies: Ankor Consultants Ltd.
Own and/or related parties’ holdings in the Company: 1,000,906 shares and 140,454 warrants in TO 2.

Morten Albrechtsen

Board member, elected 2014. (b. 1964)
Education and experience: Morten Albrechtsen has longstanding experience in CNS pharmaceuticals development, including drugs for Alzheimer’s, Parkinson’s and depression (for Enkam Pharmaceuticals), pain control (Boehringer Ingelheim and Nycomed), insomnia (Zleepax) and stroke (Boehringer Ingelheim and Enkam). Morten’s experiences run from pre-clinical and clinical development to regulatory affairs and commercialisation, and cover both biological products and small molecules.
Current assignments: CEO of FluoGuide ApS, VaccImmune IVA, VaccImmune Europe IVS and Wexotec ApS. Chairman of the Board of RetiPharma IVS. Board member of webequ IVS.
Previous assignments: CEO of Nocitech ApS, Enkam Pharmaceutical A/S, Nanovi A/S and NR Holding JUN-2010 ApS. Chairman of the Board of SUMA Care ApS and Pulmotrace ApS. CEO and board member of Innocc ApS, Panion Animal Health AB and Komplementar Appium Partners IVS. Board member of Appium Partners P/S.
Owner and active in the following companies: Wexotec ApS, webequ IVS, RetiPharma IVS, FluoGuide ApS, VaccImmune IVS, Isanan Pharma IVS, and Nanovi A/S.
Own and/or related parties’ holdings in the Company: 36,520 shares

Susana Ayesa Alvarez

Board member, elected 2017. (b. 1970)
Education and experience: Susana Ayesa Alvarez has a Ph.D. in organic chemistry from Stockholm University and a broad range of experience in the pharmaceutical industry. Susana has worked at large pharmaceutical companies such as Pharmacia & Upjohn, Johnson & Johnson, and at major biotech companies such as Medivir AB. She has solid experience in preclinical drug research and pharmaceuticals development, and as a board member has experience in clinical development and commercialisation. She was a board member of Medivir AB (2013–2016), where she has been part of the work of the R&D committee since 2014, and of ACES-SFFS (2014–2017), a non-profit association of Spanish researchers in Sweden. Currently, Susana works as Quality Control and Microbiology Manager at Johnson & Johnson Vision. She has published several scientific articles and is the co-inventor of a large number of medical patents, the majority of which have been granted.
No current assignments.
Previous assignments: Board member of Medivir Aktiebolag.
She has been neither owner nor active in any companies over the last five years.
Own and/or related parties’ holdings in the Company: 4,500 shares, and 600 CombiGene subscription rights

Peter Nilsson

Board member, elected 2014. (b. 1970)
Education and experience: Peter Nilsson received his M.Sc. in Business Admin and Economics from Lund University and is a certified public accountant who was previously a partner and business area manager of Mazars SET Revisionsbyrå AB. As an auditor, Peter has worked with both owner-managed and public companies, and has conducted exchange audits prior to listing on the NGM stock exchange. He was also director of Corporate Finance at Mazars, focusing on acquisitions and due diligence. Currently, Peter is active as CFO with a focus on strategic and business development in the Rotorbulk Group, also known as Finja.
Current assignments: Board member of PN Finanskonsult AB and Chairman of the Board of Åhus Åkeri AB.
Previous assignments over the last five years: Board member of VA Automotive AB (publ).
Owner and active in the following companies: PN Finanskonsult AB.
Own and/or related parties’ holdings in the Company: 679,967 shares and 90,662 warrants in TO 2.

Lars Thunberg

Board member, elected 2006. (b. 1966)
Education and experience: Lars Thunberg is a co-founder of CombiGene and was also its Chairman of the Board from August 2013 to October 2014. He has an M.Sc. in Business Administration and Economics from Stockholm University and Lund University.
Current assignments: Chairman of the Board of Panion Animal Health AB and board member of M & L Industriförvaltning.
Previous assignments: Board member of Högskolan Kristianstad Holding AB, Högskolan Kristianstad Uppdrag AB and Estrids Fastighet Hässleholm AB. Chairman of the Board of aXimed AB (publ), aXichem AB (publ), Camito Sweden AB, VA Automation i Hässleholm AB, SwePart verktyg i Tyringe AB, VA International AB, Ningbo Modern Tool and MV HK LTD. Board member of VA Components i Hässleholm AB, VA Tooling AB, VA Engineering i Hässleholm AB, Hardmesch AB, VA Personal AB.
Owner and active in the following companies: Panion Animal Health AB and M & L Industriförvaltning.
Own and/or related parties’ holdings in the Company: 3,772,351 shares and 199,980 warrants (Combi TO 2) held via endowment insurance.